177 related articles for article (PubMed ID: 9328174)
1. Improved 32P-postlabelling assay for the quantification of the major platinum-DNA adducts.
Welters MJ; Maliepaard M; Jacobs-Bergmans AJ; Baan RA; Schellens JH; Ma J; van der Vijgh WJ; Braakhuis BJ; Fichtinger-Schepman AM
Carcinogenesis; 1997 Sep; 18(9):1767-74. PubMed ID: 9328174
[TBL] [Abstract][Full Text] [Related]
2. Detection of platinum-DNA adducts by 32P-postlabelling.
Blommaert FA; Saris CP
Nucleic Acids Res; 1995 Apr; 23(8):1300-6. PubMed ID: 7753620
[TBL] [Abstract][Full Text] [Related]
3. 32P-postlabeling assay for the quantification of the major platinum-DNA adducts.
Pluim D; Maliepaard M; van Waardenburg RC; Beijnen JH; Schellens JH
Anal Biochem; 1999 Nov; 275(1):30-8. PubMed ID: 10542106
[TBL] [Abstract][Full Text] [Related]
4. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells.
Saris CP; van de Vaart PJ; Rietbroek RC; Blommaert FA
Carcinogenesis; 1996 Dec; 17(12):2763-9. PubMed ID: 9006117
[TBL] [Abstract][Full Text] [Related]
5. Determination of cisplatin 1,2-intrastrand guanine-guanine DNA adducts in human leukocytes by high-performance liquid chromatography coupled to inductively coupled plasma mass spectrometry.
Harrington CF; Le Pla RC; Jones GD; Thomas AL; Farmer PB
Chem Res Toxicol; 2010 Aug; 23(8):1313-21. PubMed ID: 20666396
[TBL] [Abstract][Full Text] [Related]
6. Comparison of TLC- and HPLC-32P-postlabelling assay for cisplatin-DNA adducts.
Försti A; Staffas J; Hemminki K
Carcinogenesis; 1994 Dec; 15(12):2829-34. PubMed ID: 8001242
[TBL] [Abstract][Full Text] [Related]
7. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
Bonetti A; Apostoli P; Zaninelli M; Pavanel F; Colombatti M; Cetto GL; Franceschi T; Sperotto L; Leone R
Clin Cancer Res; 1996 Nov; 2(11):1829-35. PubMed ID: 9816137
[TBL] [Abstract][Full Text] [Related]
8. Recovery of bulky DNA adducts by the regular and a modified 32P-postlabelling assay; influence of the DNA-isolation method.
Kovács K; Anna L; Rudnai P; Schoket B
Mutat Res; 2011 Mar; 721(1):95-100. PubMed ID: 21237286
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the DNA damage recognized by an antiserum elicited against cis-diamminedichloroplatinum (II)-modified DNA.
Reed E; Gupta-Burt S; Litterst CL; Poirier MC
Carcinogenesis; 1990 Dec; 11(12):2117-21. PubMed ID: 1979937
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and tissue distribution of cisplatin in nude mice: platinum levels and cisplatin-DNA adducts.
Johnsson A; Olsson C; Nygren O; Nilsson M; Seiving B; Cavallin-Stahl E
Cancer Chemother Pharmacol; 1995; 37(1-2):23-31. PubMed ID: 7497593
[TBL] [Abstract][Full Text] [Related]
11. The quantitative detection of various Pt-DNA-adducts in Chinese hamster ovary cells treated with cisplatin: application of immunochemical techniques.
Plooy AC; Fichtinger-Schepman AM; Schutte HH; van Dijk M; Lohman PH
Carcinogenesis; 1985 Apr; 6(4):561-6. PubMed ID: 4039227
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin DNA adduct detection and depurination measured by 32P DNA radiolabeling and two-dimensional thin-layer chromatography: a time and concentration study.
Farah N; Dresner HS; Searles KJ; Winiarsky R; Moosikasuwan M; Cajigas A; Hahm S; Steinberg JJ
Cancer Invest; 2000; 18(4):314-26. PubMed ID: 10808367
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
Meerum Terwogt JM; Groenewegen G; Pluim D; Maliepaard M; Tibben MM; Huisman A; ten Bokkel Huinink WW; Schot M; Welbank H; Voest EE; Beijnen JH; Schellens JM
Cancer Chemother Pharmacol; 2002 Mar; 49(3):201-10. PubMed ID: 11935212
[TBL] [Abstract][Full Text] [Related]
14. 32P-postlabelling method for the detection of 7-alkylguanine adducts formed by the reaction of different 1,2-alkyl epoxides with DNA.
Kumar R; Staffas J; Försti A; Hemminki K
Carcinogenesis; 1995 Mar; 16(3):483-9. PubMed ID: 7697802
[TBL] [Abstract][Full Text] [Related]
15. 32P-postlabelling and mass spectrometric methods for analysis of bulky, polyaromatic carcinogen-DNA adducts in humans.
Talaska G; Roh JH; Getek T
J Chromatogr; 1992 Sep; 580(1-2):293-323. PubMed ID: 1400827
[TBL] [Abstract][Full Text] [Related]
16. Influence of the degree of DNA modification on the immunochemical determination of cisplatin-DNA adduct levels.
Fichtinger-Schepman AM; Baan RA; Berends F
Carcinogenesis; 1989 Dec; 10(12):2367-9. PubMed ID: 2591026
[TBL] [Abstract][Full Text] [Related]
17. Use of the 32P-postlabelling assay to study transplacental carcinogens and transplacental carcinogenesis.
Randerath K; Liehr JG; Gladek A; Randerath E
IARC Sci Publ; 1989; (96):189-205. PubMed ID: 2509347
[TBL] [Abstract][Full Text] [Related]
18. Detection and characterization of carcinogen-DNA adducts in exfoliated urothelial cells from 4-aminobiphenyl-treated dogs by 32P-postlabelling and subsequent thin-layer and high-pressure liquid chromatography.
Talaska G; Dooley KL; Kadlubar FF
Carcinogenesis; 1990 Apr; 11(4):639-46. PubMed ID: 2323002
[TBL] [Abstract][Full Text] [Related]
19. One-milliliter wet-digestion for inductively coupled plasma mass spectrometry (ICP-MS): determination of platinum-DNA adducts in cells treated with platinum(II) complexes.
Yamada K; Kato N; Takagi A; Koi M; Hemmi H
Anal Bioanal Chem; 2005 Aug; 382(7):1702-7. PubMed ID: 15959768
[TBL] [Abstract][Full Text] [Related]
20. Platinum concentrations and DNA adduct levels in tumors and organs of cisplatin-treated LOU/M rats inoculated with cisplatin-sensitive or -resistant immunoglobulin M immunocytoma.
Fichtinger-Schepman AM; Vendrik CP; van Dijk-Knijnenburg WC; de Jong WH; van der Minnen AC; Claessen AM; van der Velde-Visser SD; de Groot G; Wubs KL; Steerenberg PA
Cancer Res; 1989 Jun; 49(11):2862-7. PubMed ID: 2720647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
